When the BMI is below 40, but morbid obesity is documented by the anesthesiologist (no other documentation regarding the patient’s obesity is recorded in the health record), is it appropriate to code morbid obesity or is a query recommended?
Answer:
Codes for overweight, obesity or morbid obesity are assigned based on the provider’s documentation of these conditions.
Therefore, if morbid obesity is documented, assign code E66.01, morbid (severe) obesity due to excess calories.
While the BMI is used as a screening tool for patients who are overweight or obese, there is no coding rule that defines what BMI values correspond to obesity or morbid obesity since the conditions are coded only when diagnosed and documented by the provider or another physician involved in the patient’s care.
AHA Coding Clinic, Fourth Quarter 2018, pp. 79 – 80
Should you code morbid obesity when a patient has a BMI of 36?
This is one of my favorite questions to ask physicians,
coders and healthcare executives when I am teaching. Why? Because it is
guaranteed to elicit the following three responses:
A.Yes, absolutely! As long as the patient has 3 or
more chronic conditions….
B.No, I never use that code. I don’t want to upset
anyone with open notes and patient portals…
C.No, morbid obesity should only be coded with a
BMI of 40.0 or more…
One-third of the audience will select “A” as the correct
answer, one-third will select “B” and one-third will choose “C”. This scenario
will play out the same way in Miami, Philadelphia, Austin, Chicago, Little Rock
or any other city in America. Why? Because it is an urban coding legend…
Urban Coding Legend #1:
Morbid obesity should always be coded when a patient has a BMI greater than 35.0 and 3 or more chronic conditions.
True
or False?
The answer is false.
Obesity is defined and classified by both the United States Preventive Task
Force and The National Institutes of Health and National Heart, Lung, and Blood
Institute using the following classification:
Obesity is divided into three classes. The third class, extreme obesity,
also called severe obesity, is synonymous with the term “morbid obesity” and is
diagnosed based on a BMI of 40.0 or greater.
According to the NHLBI: A person with a BMI (body mass index) value of 40 or greater would be
considered morbidly obese. An adult who has a BMI of 30 or higher is considered
merely "obese.". Grade 3 overweight (commonly called severe or morbidobesity) is a BMI greater than or equal to 40 kg/m2.
The Origins
This “urban coding legend” originated from the corridors of “risk adjustment optimization” teams, searching for “low hanging fruit” and the clinical evidence to “support” it.
The following events, recommendations and guidelines set the stage and a story was born…
1.USPTF
Updates Recommendations
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued
updated recommendations regarding the screening and management of obesity for
adults.
2.The American
Academy of Family Physicians
The AAFP publishes clinical evidence to support the USPTF Recommendations:
From the AAFP:
In patients with a BMI of
25 kg/m2 or greater, further evaluation of risk factors is required. Blood
pressure and lipid levels should be measured, and fasting glucose tested.
Bariatric surgery may be considered in adults who have
not achieved weight loss with dietary or other treatments and who have a BMI of
40 kg/m2 or greater, or for those who have a BMI of 35 kg/m2 or greater with
significant obesity-related comorbidities (e.g., severe hypertension, type 2
diabetes, obstructive sleep apnea).
Bariatric
surgery may also benefit patients with obesity-related comorbidities who have a
BMI of 35 kg/m2 or lower, but it is not routinely recommended for these
patients
3.Medicare
Payment Guidelines:
In response to
the updated USPTF Guidelines and AAFP clinical evidence supporting the benefit
of gastric bypass surgery as a treatment for obesity Medicare updated their
payment policies for this procedure:
Covered Bariatric Surgery Procedures for Treatment
of Co-Morbid Conditions Related to Morbid Obesity
Medicare contractors acting
within their respective jurisdictions may determine coverage of stand-alone LSG
for the treatment of co-morbid conditions related to obesity in Medicare
beneficiaries only when all of the
following conditions are satisfied:
·The beneficiary has a body-mass index (BMI) ≥ 35
kg/m2;
·The beneficiary has at least one co-morbidity
related to obesity; and
·The beneficiary has been previously unsuccessful
with medical treatment for obesity.
4.Revised HCC
Model
On April 1, 2013 CMS released the Announcement
of Calendar Year (CY) 2014 Medicare Advantage Capitation Rates and Medicare
Advantage and Part D Payment Policies and Final Call Letter.
In the Final Call Letter, CMS confirmed that they would be
implementing the updated, clinically revised CMS-HCC risk adjustment model
proposed in the Advance Noticefor CY2014. The new model expanded the current number of Condition
Categories from 70 to 79.
Under the revised model, the “Metabolic” category was
expanded from one (HCC 21) to three (HCC 21, HCC 22, HCC 23). Given the
prevalence of obesity, the new HCC 22 “morbid obesity” was quickly identified
as a “low hanging fruit” for optimization teams. By coding morbid obesity with
a BMI of 35.0 vs. 40.0 the prevalence rates, A.K.A. payments, to the plans
would greatly increase.
The previous three events were loosely woven together to
form support for the practice and an urban coding legend rose like a phoenix
from the ashes.
HCC 22 includes the following ICD-10 Codes:
Do you see a BMI under 40 in the above chart? Remember clinical, coding and payment guidelines can not be substituted to fit the situation as needed.
The study, designed to promote lymph flow and optimize body mass index (BMI) after breast cancer surgery, saw a 97% success rate for patients in the program one year after surgery.
Newswise — Viewed as one of the most unfortunate outcomes of breast cancer treatment, lymphedema is characterized by an accumulation of lymph fluid in the interstitial spaces of the affected limb, leading to chronic ipsilateral limb swelling causing psychosocial distress and physical challenges for patients.
Even conservative estimates suggest that 3% of women who have had sentinel lymph node biopsy and 20% of those who have had axillary lymph node dissection may develop lymphedema a year after breast cancer surgery. Two established risk factors for lymphedema are compromised lymphatic drainage and higher body mass index (BMI).
To date, there is little high-quality evidence to support the role of precautionary life-style strategies in reducing these risk factors.
Now, a team of researchers led by Mei R. Fu, PhD, RN, ACNS-BC, FAAN, associate professor of Chronic Disease Management at the New York University College of Nursing (NYUCN) conducted a pilot study to evaluate a patient-centered educational and behavioral self-care program called The Optimal Lymph Flow. The goals of the program were to promote lymph flow and optimize BMI over a 12-month period after breast cancer surgery. Findings of the study entitled “Proactive Approach to Lymphedema Risk Reduction: A Prospective Study” was published first on-line in the Annals of Surgical Oncology(May 2014). They offer initial evidence in support of a shift in the focus of lymphedema care away from treatment and toward proactive risk reduction.
“A patient-centered educational and behavioral program focusing on self-care strategies appears to be an effective way to reduce the risk of lymphedema in survivors of breast cancer,” said Dr. Fu. “Based on these study findings, the New York University College of Nursing has established this patient-centered lymphedema risk reduction program as a web-based avatar technology intervention.”
Dr. Fu’s team enrolled 140 women and followed them for 12 months after surgery for breast cancer. Women who had metastatic breast cancer, a history of breast cancer and lymphedema, or bilateral breast cancer were excluded from the study.
Nearly 60% of patients had undergone axillary lymph node dissection, and approximately 40% had undergone sentinel lymph node biopsy. Although more women in the dissection group had had a mastectomy and chemotherapy than in the biopsy group, both groups were similar in terms of body weight and BMI.
The educational and behavioral program consisted of an assortment of self-care strategies. They included shoulder mobility exercises, muscle-tightening deep breathing, muscle-tightening pumping exercises, and large-muscle exercises to promote lymph flow and drainage (eg, walking, marching, dancing, swimming, yoga, tai chi). In addition, to maintain their preoperative BMI, the women were offered nutritional instructions and encouraged to follow a balanced, portion-appropriate diet.
Limb volume change assessed by an infrared perometer and BMI via a bioimpedance device were outcome measures. Assessments were performed before surgery (baseline) and after surgery (at 2–4 weeks, 6 months, and 12 months). Lymphedema was defined as ≥ 10% increase in limb volume from baseline in the ipsilateral arm compared with changes in the contralateral arm.
Of the 134 women who completed the study, 97% of patients maintained and improved their preoperative limb volume and BMI at 12 months after surgery. No patients exceeded a 10% increase in limb volume at 12-month follow-up. No patients reported injury or discomfort associated with The Optimal Lymph Flow program at any follow-up visit, according to the investigators.
“The Optimal Lymph Flow Program promotes lymph flow and optimal [BMI] by empowering, rather than inhibiting, how survivors live their lives,” said Dr. Fu. “Its underlying premise is ‘what to do’ rather than ‘what to avoid.”
These preliminary findings suggest that self-care strategies such as The Optimal Lymph Flow program may prove to be an effective way to reduce the risk of lymphedema in survivors of breast cancer. In fact, nearly 90% of the women studied reported that the program helped them to understand how to reduce their risk of lymphedema as well as dispel their fear and anxiety about developing this side effect. Future research requires a larger study with a randomized, controlled design to confirm the program’s overall benefits.